Opprettet 2006 (Frankrike), I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome egen 2757 tilknyttede merkevarer og 17478 konkurrerende merkevarer. I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome-merket eies av SANOFI, et selskap oppført i Paris. Selskapets internasjonale verdipapiridentifikasjonsnummer (ISIN) er FR0000120578. Bransjen I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome opererer i, er Legemiddelprodusenter.

I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome er et varemerke som tilhører SANOFI (SAN) Nyheter

Internasjonalt innskudd : 2006 Bransje Legemiddelprodusenter

Alle nyhetene Marketscreener-logo
SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome)

loader
Børs: Mer informasjon om SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome) Marketscreener-logo